Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced products are derived from our proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We currently have five clinical-stage development programs. In addition, we have a deep and diverse pipeline of preclinical programs as well as a platform capable of unlocking new drug targets. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.59 |
| Quarterly EPS Est: | -0.4 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research
